Figure 7 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies

<p>TAGL as a predictive marker for dasatinib sensitivity. <b>A,</b> Western blot of control and <i>TAGLN</i>-KO cells in Hs578T (top) and BT-549 (bottom) cells. <b>B,</b> Representative immunofluorescence of Hs578T and BT549 control and <i>TAGLN</i>-KO cells, stained with αTAGL (green) and DAPI (blue). Scale bar, 50 μm. <b>C,</b> Cell proliferation in control (black) and <i>TAGLN</i>-KO (purple) cells measured by MTT assays over 72 hours. <b>D,</b> Relative percentage of migrated cells in control and <i>TAGLN</i>-KO cells, assessed by transwell assays. In <b>C</b> and <b>D</b>, values represent the mean ± SEM of at least three experimental replicates, and statistical significance was determined using one-way ANOVA. <b>E,</b> Drug–response curves for cell viability of control and <i>TAGLN</i>-KO cells treated with dasatinib at increasing concentrations. <b>F,</b> Western blot of known dasatinib targets in control and <i>TAGLN</i>-KO cells. <b>G,</b> Data from the <i>DepMap</i> portal showing the correlation between <i>TAGLN</i> and <i>PDGFRB</i> in breast cancer cell lines. <b>H,</b> Western blot of PDGFRβ in <i>TAGLN</i>-KO and cells and clones constitutively expressing <i>PDGFRB</i>. <b>I,</b> Drug–response curves for cell viability of <i>TAGLN</i>-KO and <i>TAGLN</i>-KO/<i>PBGFRB</i> cells treated with dasatinib at increasing concentrations. In <b>E</b> and <b>I</b>, solid lines represent the mean of three biological replicates performed in technical replicates. The dashed line indicates their IC<sub>50</sub> value. **, <i>P</i> < 0.01; ****, <i>P</i> < 0.0001; ns, not significant.</p>